HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Andrew Blauvelt Selected Research

Certolizumab Pegol

1/2019Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials.
8/2018Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2).
8/2018Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Andrew Blauvelt Research Topics

Disease

123Psoriasis (Pustulosis Palmaris et Plantaris)
03/2024 - 10/2002
51Atopic Dermatitis (Atopic Eczema)
05/2024 - 02/2003
21Infections
03/2024 - 03/2002
17Eczema
05/2024 - 12/2016
17Inflammation (Inflammations)
04/2024 - 10/2002
14Neoplasms (Cancer)
03/2024 - 04/2003
9Skin Diseases (Skin Disease)
12/2023 - 10/2009
9Pruritus (Itching)
10/2023 - 12/2016
9Conjunctivitis
03/2023 - 12/2016
7Injection Site Reaction
09/2021 - 12/2016
6Psoriatic Arthritis
02/2024 - 08/2015
6HIV Infections (HIV Infection)
01/2013 - 08/2002
5Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
01/2023 - 07/2016
5Oral Candidiasis (Thrush)
01/2023 - 01/2021
5Body Weight (Weight, Body)
01/2023 - 01/2017
4Nasopharyngitis
01/2023 - 01/2016
4Respiratory Tract Infections (Respiratory Tract Infection)
01/2023 - 10/2020
4Candidiasis (Moniliasis)
10/2016 - 11/2010
3Erythema
05/2024 - 03/2019
3Tuberculosis (Tuberculoses)
10/2023 - 01/2023
3Skin Neoplasms (Skin Cancer)
01/2023 - 10/2016
3Pain (Aches)
11/2021 - 01/2017
3Rheumatoid Arthritis
03/2021 - 01/2017
3Communicable Diseases (Infectious Diseases)
01/2021 - 03/2004
3Asthma (Bronchial Asthma)
01/2021 - 10/2017
2Edema (Dropsy)
05/2024 - 03/2012
2Acne Vulgaris
03/2024 - 01/2021
2Herpes Zoster
03/2024 - 09/2021
2Axial Spondyloarthritis
02/2024 - 01/2019
2Headache (Headaches)
01/2023 - 01/2021
2Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2023 - 11/2021
2COVID-19
11/2022 - 01/2021
2Crohn Disease (Crohn's Disease)
02/2020 - 01/2019
2Hepatitis B
10/2016 - 01/2012
2Soft Tissue Infections
08/2013 - 05/2010
2Contact Dermatitis (Eczema, Contact)
03/2012 - 09/2011
2Hyperplasia
02/2011 - 11/2010
1Atherosclerosis
04/2024
1Folliculitis (Sycosis)
03/2024
1Ankylosing Spondylitis
02/2024
1Non-Radiographic Axial Spondyloarthritis
02/2024
1Seborrheic Dermatitis
01/2024

Drug/Important Bio-Agent (IBA)

29ixekizumabIBA
03/2024 - 12/2014
28Interleukin-17 (Interleukin 17)IBA
03/2024 - 12/2007
27Monoclonal AntibodiesIBA
04/2024 - 10/2009
26secukinumabIBA
03/2024 - 08/2015
25Immunoglobulin A (IgA)IBA
05/2024 - 10/2016
23dupilumabIBA
02/2024 - 01/2016
22CytokinesIBA
12/2023 - 10/2002
20InterleukinsIBA
04/2024 - 09/2009
15guselkumabIBA
02/2024 - 03/2017
14Interleukin-23 (Interleukin 23)IBA
12/2023 - 12/2007
14Etanercept (Enbrel)FDA Link
01/2022 - 06/2006
13Adalimumab (Humira)FDA Link
11/2023 - 05/2011
12Ustekinumab (CNTO 1275)FDA Link
01/2023 - 01/2012
11bimekizumabIBA
03/2024 - 08/2018
8Adrenal Cortex Hormones (Corticosteroids)IBA
12/2023 - 03/2002
7tralokinumabIBA
04/2024 - 10/2022
7Interleukin-13IBA
04/2024 - 01/2016
7deucravacitinibIBA
03/2024 - 01/2022
7TYK2 Kinase (Tyrosine Kinase 2)IBA
03/2024 - 01/2021
7risankizumabIBA
12/2023 - 01/2017
6apremilastIBA
03/2024 - 12/2022
5lebrikizumabIBA
05/2024 - 01/2020
5upadacitinibIBA
02/2024 - 01/2021
5Prostaglandins AIBA
12/2023 - 10/2012
5Interleukin-12 (IL 12)IBA
10/2023 - 10/2009
5Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
08/2018 - 10/2012
4ruxolitinibIBA
05/2024 - 01/2023
4Biomarkers (Surrogate Marker)IBA
04/2024 - 01/2020
4Infliximab (Remicade)FDA Link
11/2023 - 05/2010
4abrocitinibIBA
01/2023 - 01/2022
4omega-Chloroacetophenone (Mace)IBA
06/2022 - 01/2019
4CyclinsIBA
01/2022 - 06/2003
4brodalumabIBA
05/2020 - 01/2017
4Interleukin-4 (Interleukin 4)IBA
01/2019 - 01/2016
4Immunoglobulin G (IgG)IBA
01/2018 - 01/2008
4Interleukin-22 (IL-22)IBA
02/2011 - 12/2007
3Phosphodiesterase 4 InhibitorsIBA
12/2023 - 12/2022
3tildrakizumabIBA
10/2023 - 01/2017
3Interleukin-23 Subunit p19IBA
01/2023 - 10/2009
3AntigensIBA
01/2022 - 03/2004
3Tumor Necrosis Factor InhibitorsIBA
01/2021 - 01/2012
3VaccinesIBA
01/2019 - 12/2005
3Certolizumab PegolFDA Link
01/2019 - 08/2018
3Methotrexate (Mexate)FDA LinkGeneric
10/2016 - 06/2006
3DC-specific ICAM-3 grabbing nonintegrin (DC-SIGN)IBA
03/2008 - 08/2002
2Janus KinasesIBA
01/2022 - 01/2021
2Janus Kinase InhibitorsIBA
01/2022 - 01/2021
2AntibodiesIBA
01/2019 - 10/2018
2Interleukin-4 Receptors (Interleukin 4 Receptor)IBA
01/2019 - 12/2016
2Interleukin-17 ReceptorsIBA
12/2018 - 01/2018
2Interleukin-10 (Interleukin 10)IBA
07/2015 - 10/2002
2efalizumab (Raptiva)FDA Link
05/2008 - 02/2007
2DNA (Deoxyribonucleic Acid)IBA
01/2008 - 10/2002
2C-Type Lectins (C-Type Lectin)IBA
12/2005 - 03/2004
1RoflumilastIBA
01/2024

Therapy/Procedure

33Therapeutics
03/2024 - 05/2008
5Biological Therapy
10/2021 - 08/2013
2Critical Care (Surgical Intensive Care)
01/2021 - 12/2020